» Articles » PMID: 34151858

Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease

Overview
Publisher Sage Publications
Specialty Neurology
Date 2021 Jun 21
PMID 34151858
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuropsychiatric symptoms (NPS) are the most common non-motor symptom in Parkinson's disease (PD).

Objective: To investigate the association between the burden of NPS and motor prognosis in patients with PD.

Methods: We enrolled 329 drug-naïve patients with PD, who was non-demented and followed-up≥2 years after their first visit to the clinic with baseline dopamine transporter (DAT) imaging and neuropsychiatric inventory (NPI) scores. We performed a survival analysis and a linear mixed model analysis to assess longitudinal motor outcomes according to the NPI total score.

Results: The Kaplan-Meier analysis showed no difference in the development of levodopa-induced dyskinesia and wearing-off according to the NPI total score. However, higher burden of NPI total score was associated with earlier freezing of gait (FOG) development in the time-dependent Cox regression models after adjusting for age at symptom onset, sex, disease duration, Unified PD Rating Scale motor score, baseline Mini-Mental State Examination score, DAT activity in the posterior putamen and levodopa-equivalent daily dose (LEDD) (Hazard ratio 1.047, p = 0.002). A linear mixed model analysis revealed that patients with a higher NPI total score had a more rapid LEDD increment (NPI×time, p = 0.003). Among 52 patients with PD who eventually developed FOG during the follow-up period, there was a significant correlation between the NPI total score and time with FOG development (γ= -0.472; p = 0.001) after adjusting for confounding factors.

Conclusion: The present study demonstrated that the severity of NPS is a predictor of early freezing and motor progression in patients with PD.

Citing Articles

A meta-analysis identifies factors predicting the future development of freezing of gait in Parkinson's disease.

Herman T, Barer Y, Bitan M, Sobol S, Giladi N, Hausdorff J NPJ Parkinsons Dis. 2023; 9(1):158.

PMID: 38049430 PMC: 10696025. DOI: 10.1038/s41531-023-00600-2.


Gait Declines Differentially in, and Improves Prediction of, People with Parkinson's Disease Converting to a Freezing of Gait Phenotype.

Virmani T, Landes R, Pillai L, Glover A, Larson-Prior L, Prior F J Parkinsons Dis. 2023; 13(6):961-973.

PMID: 37522218 PMC: 10578275. DOI: 10.3233/JPD-230020.


Prevalence and Risk Factors of Neuropsychiatric Symptoms in Institutionalized Patients with Parkinson's Disease in Taiwan: A Nationwide Observational Study.

Chang Y, Chien C, Hsieh S, Huang L, Lin C, Hsu C Healthcare (Basel). 2023; 11(2).

PMID: 36673626 PMC: 9859113. DOI: 10.3390/healthcare11020258.


Association of Depression With Early Occurrence of Postural Instability in Parkinson's Disease.

Hwang Y, Jo S, Park K, Lee S, Lee S, Chung S J Mov Disord. 2022; 16(1):68-78.

PMID: 36537065 PMC: 9978256. DOI: 10.14802/jmd.22091.


Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease.

Cui C, Lewis S Front Hum Neurosci. 2021; 15:741918.

PMID: 34795568 PMC: 8592896. DOI: 10.3389/fnhum.2021.741918.